Combination of bromodomain and extra-terminal domain (BET) protein inhibitor and proteasome inhibitor improved therapeutic outcome in patients with advanced multiple myeloma by promoting endoplasmic reticulum stress and Bim-dependent apoptosis (Qian et al., 2018). Here, BCL2L11 is linked to plasma cell myeloma.